FDA Reviewing Popular Peptides: What Researchers Should Know Before July 23
By RUOcodes.com Research Team
Published: · Updated: Sep 6, 2026
Full recap of the FDA PCAC July 2026 peptide review: which compounds were considered, vote outcomes, and the compounding implications for researchers.
For research and educational purposes only. Not medical advice. Direct Answer On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet to review seven peptides — BPC-157 , KPV , TB-500 , MOTS-c , Emideltide (DSIP), Semax , and Epitalon — for possible inclusion on the 503A Bulk Drug Substances List. FDA's pre-meeting briefing documents already propose rejecting all fourteen substance designations, citing insufficient characterization data and inadequate human safety/effectiveness evidence. A negative recommendation is not a ban; it does not change the compounds' current legal status as research chemicals. The PCAC meets July 23–24, 2026 at FDA's White Oak Campus in Silver Spring, MD FDA's briefing documents recommend against adding any of the seven peptides to the 503A Bulks List A second PCAC meeting is scheduled before the end of February 2027 for GHK-Cu , Melanotan II , LL-37, Dihexa acetate, and PEG-MGF The most consequential peptide regulatory event of 2026 is three weeks away. On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee will meet at the White Oak Campus in Silver Spring, Maryland, to review seven of the most widely researched peptides in the biohacking and functional medicine world. The FDA has already published its pre-meeting briefing documents, and those documents make the agency's position heading into the meeting unmistakably clear. Researchers and practitioners who are paying attention have time to understand what is coming and make informed decisions. Those who are not paying attention are going to be caught off guard. This post covers everything you need to know before the gavel drops. What the PCAC Is and Why This Meeting Matters The Pharmacy Compounding Advisory Committee is an independent panel of scientific and medical experts appointed by the FDA to evaluate bulk drug substances for potential inclusion on the Section 503A Bulk Drug Substances List. That list is not a mino…
← Back to Blog